179 related articles for article (PubMed ID: 19097174)
21. A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 AML patients in China.
Zheng J; Wang X; Hu Y; Yang J; Liu J; He Y; Gong Q; Yao J; Li X; Du W; Huang S
Cytometry B Clin Cytom; 2008 Jan; 74(1):25-9. PubMed ID: 18061959
[TBL] [Abstract][Full Text] [Related]
22. High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome.
Chamuleau ME; van de Loosdrecht AA; Hess CJ; Janssen JJ; Zevenbergen A; Delwel R; Valk PJ; Löwenberg B; Ossenkoppele GJ
Haematologica; 2008 Dec; 93(12):1894-8. PubMed ID: 19050070
[TBL] [Abstract][Full Text] [Related]
23. [Expression of c-MPL in leukemic stem cells from acute myeloid leukemia patients].
Yu P; Qiu SW; Rao Q; Lin D; Xing HY; Tang KJ; Tian Z; Wang M; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1052-5. PubMed ID: 23114117
[TBL] [Abstract][Full Text] [Related]
24. Expression of VEGF-C and its receptor VEGFR-3 in the bone marrow of patients with acute myeloid leukaemia.
Liersch R; Schliemann C; Bieker R; Hintelmann H; Buechner T; Berdel WE; Mesters RM
Leuk Res; 2008 Jun; 32(6):954-61. PubMed ID: 18006056
[TBL] [Abstract][Full Text] [Related]
25. Acute myeloid leukemia and transcription factors: role of erythroid Krüppel-like factor (EKLF).
Ayala R; Martínez-López J; Gilsanz F
Cancer Cell Int; 2012 Jun; 12(1):25. PubMed ID: 22676581
[TBL] [Abstract][Full Text] [Related]
26. Identification of the translocation t(15;17) in acute myeloid leukemia (AML) initially classified as FAB M1: case report and review of the literature.
Braham Jmili N; Omri H; Senana Sendi H; Fekih S; Hizem S; Sriha B; Khelif A; Saad A; Kortas M
Clin Lab; 2006; 52(3-4):125-30. PubMed ID: 16584058
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of beta-catenin and topoisomerase IIalpha in de novo acute myeloid leukemia.
Chen CC; Gau JP; You JY; Lee KD; Yu YB; Lu CH; Lin JT; Lan C; Lo WH; Liu JM; Yang CF
Am J Hematol; 2009 Feb; 84(2):87-92. PubMed ID: 19127593
[TBL] [Abstract][Full Text] [Related]
28. De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance.
Gahn B; Haase D; Unterhalt M; Drescher M; Schoch C; Fonatsch C; Terstappen LW; Hiddemann W; Büchner T; Bennett JM; Wörmann B
Leukemia; 1996 Jun; 10(6):946-51. PubMed ID: 8667650
[TBL] [Abstract][Full Text] [Related]
29. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
[TBL] [Abstract][Full Text] [Related]
31. The combined expression of HOXA4 and MEIS1 is an independent prognostic factor in patients with AML.
Zangenberg M; Grubach L; Aggerholm A; Silkjaer T; Juhl-Christensen C; Nyvold CG; Kjeldsen E; Ommen HB; Hokland P
Eur J Haematol; 2009 Nov; 83(5):439-48. PubMed ID: 19563517
[TBL] [Abstract][Full Text] [Related]
32. Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals.
Ommen HB; Nyvold CG; Braendstrup K; Andersen BL; Ommen IB; Hasle H; Hokland P; Ostergaard M
Br J Haematol; 2008 Jun; 141(6):782-91. PubMed ID: 18410450
[TBL] [Abstract][Full Text] [Related]
33. TWIST-1 promotes cell growth, drug resistance and progenitor clonogenic capacities in myeloid leukemia and is a novel poor prognostic factor in acute myeloid leukemia.
Wang N; Guo D; Zhao YY; Dong CY; Liu XY; Yang BX; Wang SW; Wang L; Liu QG; Ren Q; Lin YM; Ma XT
Oncotarget; 2015 Aug; 6(25):20977-92. PubMed ID: 26023795
[TBL] [Abstract][Full Text] [Related]
34. Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia.
Schliemann C; Bieker R; Padro T; Kessler T; Hintelmann H; Buchner T; Berdel WE; Mesters RM
Haematologica; 2006 Sep; 91(9):1203-11. PubMed ID: 16956819
[TBL] [Abstract][Full Text] [Related]
35. Sequential influences of leukemia-specific and genetic factors on p-glycoprotein expression in blasts from 817 patients entered into the National Cancer Research Network acute myeloid leukemia 14 and 15 trials.
Seedhouse CH; Grundy M; White P; Li Y; Fisher J; Yakunina D; Moorman AV; Hoy T; Russell N; Burnett A; Pallis M;
Clin Cancer Res; 2007 Dec; 13(23):7059-66. PubMed ID: 18056183
[TBL] [Abstract][Full Text] [Related]
36. GATA Factor-Dependent Positive-Feedback Circuit in Acute Myeloid Leukemia Cells.
Katsumura KR; Ong IM; DeVilbiss AW; Sanalkumar R; Bresnick EH
Cell Rep; 2016 Aug; 16(9):2428-41. PubMed ID: 27545880
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities.
Vicente C; Vazquez I; Conchillo A; García-Sánchez MA; Marcotegui N; Fuster O; González M; Calasanz MJ; Lahortiga I; Odero MD
Leukemia; 2012 Mar; 26(3):550-4. PubMed ID: 21904383
[No Abstract] [Full Text] [Related]
38. M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience.
Pulsoni A; Iacobelli S; Bernardi M; Borgia M; Camera A; Cantore N; Di Raimondo F; Fazi P; Ferrara F; Leoni F; Liso V; Mancini M; Marmont F; Matturro A; Maurillo L; Melillo L; Meloni G; Mirto S; Specchia G; Valentini CG; Venditti A; Leone G; Foà R; Mandelli F; Pagano L
Haematologica; 2008 Jul; 93(7):1025-32. PubMed ID: 18508801
[TBL] [Abstract][Full Text] [Related]
39. Genetic alteration patterns and clinical outcomes of elderly and secondary acute myeloid leukemia.
Wang SY; Cheng WY; Mao YF; Zhu YM; Liu FJ; Ma TT; Shen Y
Hematol Oncol; 2019 Oct; 37(4):456-463. PubMed ID: 31348835
[TBL] [Abstract][Full Text] [Related]
40. Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia.
Hussein K; Jahagirdar B; Gupta P; Burns L; Larsen K; Weisdorf D
Am J Hematol; 2008 Jun; 83(6):446-50. PubMed ID: 18247382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
